Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals has hit a new 52-week low, continuing a six-day decline that has seen an overall decrease of 8.51%. The stock is trading below multiple moving averages and has declined 17.28% over the past year, contrasting with the Sensex's 6.03% gain during the same period.

Alembic Pharmaceuticals has reached a new 52-week low, reflecting significant volatility and a 7.79% decline over the past five days. The company has underperformed its sector and is trading below its moving averages, with a one-year performance drop of 15.89%, contrasting with the Sensex's gains.

Alembic Pharmaceuticals has faced a significant decline in stock performance, losing 5.28% on February 4, 2025, and underperforming its sector. Over the past month, the company has seen a 16.92% drop, contrasting sharply with the Sensex's minor decrease, indicating ongoing challenges for the midcap pharmaceutical firm.

Alembic Pharmaceuticals has faced a significant decline in stock performance, losing 5.28% on February 4, 2025, and underperforming its sector. Over the past month, the company has seen a 16.92% drop, contrasting sharply with the Sensex's minor decrease, indicating ongoing challenges for the midcap pharmaceutical firm.

Alembic Pharmaceuticals has faced a notable decline, with shares falling for six consecutive days and a total drop of 16.87%. The stock underperformed against its sector and is trading below key moving averages, indicating ongoing challenges in the competitive pharmaceuticals industry.

Alembic Pharmaceuticals' stock has faced notable declines, losing 6.0% on January 24, 2025, and underperforming its sector. The stock has fallen for four consecutive days, with significant intraday volatility and trading below key moving averages, indicating ongoing challenges in the market.

Alembic Pharmaceuticals has experienced a recent evaluation adjustment, highlighting concerns about its declining operating profit over five years. While liquidity management poses challenges, the company shows strong debt servicing capacity. Its competitive return on capital employed and appealing valuation contrast with a sideways stock trend and a discount to historical valuations.

Alembic Pharmaceuticals Ltd. experienced notable trading activity on January 17, 2025, with a significant increase, indicating a potential trend reversal after previous declines. The stock is currently above its 5-day moving average but below longer-term averages, reflecting a mixed trend amid a challenging market.

Alembic Pharmaceuticals Ltd. has recently undergone a revision in its score, reflecting ongoing challenges in the market. The stock has been added to MarketsMOJO's list, as it continues to trade below key moving averages and has shown a notable decline over the past month, underperforming its sector. Investors remain vigilant amid these developments.

Alembic Pharmaceuticals Ltd. has seen a revision in its score following a strong performance, including a notable increase on January 6, 2025. The stock has been added to MarketsMOJO's list, reflecting its consistent gains and resilience against market fluctuations. Analysts highlight its favorable position relative to key moving averages and sector performance.

Alembic Pharmaceuticals has experienced a revision in its score following a recent decline in stock performance. Despite a short-term downturn, the company maintains a solid long-term outlook, with moving averages indicating resilience. The stock has been added to MarketsMOJO's list, reflecting its ongoing potential in the pharmaceutical sector.

On November 25, 2024, Alembic Pharmaceuticals . saw a 4.15% increase in its stock, outperforming the sector by 2.96%. According to MarketsMOJO, the current stock call for the company is 'Hold', based on its recent performance and market trends. Alembic Pharmaceuticals . has been consistently gaining for the last 6 days and is currently trading higher than its moving averages. It has also outperformed the Sensex in the last 1 day and 1 month, indicating a positive trend. As a leading player in the pharmaceuticals and drugs industry, Alembic Pharmaceuticals . continues to show strong performance and investors can monitor the stock for potential opportunities.

Alembic Pharmaceuticals, a largecap company in the pharmaceuticals and drugs industry, has reported a flat performance in the second quarter of fiscal year 2024-2025. However, the company has shown strong operating cash flow and the highest net sales in the last five quarters. The profit before tax has also seen a growth of 21.14% year on year. On the other hand, the debtors turnover ratio and non-operating income need improvement. MarketsMOJO has given a 'Hold' call for the company's stock, indicating a neutral stance.

On November 8th, Alembic Pharmaceuticals .'s stock price dropped by -3.18%, falling below the sector average by -2.45%. The stock has been on a downward trend for the past two days, with a total loss of -8.16%. Despite this, the stock remains above its 200-day moving average but below its shorter-term averages. MarketsMOJO has given a 'Hold' rating for the company's stock.

On November 7th, 2024, Alembic Pharmaceuticals Ltd. experienced a -4.2% decline in stock price due to underperformance in the sector, falling -1.7% below the sector average. Despite this, the stock's moving averages remain higher than the 100-day and 200-day averages, and it has outperformed the overall market in the long term. MarketsMOJO has given a 'Hold' call for the stock.

On October 31st, 2024, Alembic Pharmaceuticals . saw a 3.27% increase in its stock price, outperforming the sector by 2.37%. This marks the second consecutive day of gains for the company, with a total increase of 4.88% in the past two days. The stock is currently trading higher than its moving averages and has been given a 'Hold' call by MarketsMOJO. Despite the overall market performance being slightly negative, Alembic Pharmaceuticals . has outperformed the Sensex in the past day and month, showcasing its strength as a leading player in the industry.

Alembic Pharmaceuticals Ltd. is a leading pharmaceutical company in the largecap industry, with a strong presence in the market. Despite experiencing a decline of -3.38% on October 22, 2024, the stock is currently trading higher than its 100-day and 200-day moving averages. According to MarketsMOJO, the current recommendation for the stock is 'Hold', based on its recent performance and market trends. While it has underperformed the Sensex in the past day and month, Alembic remains a well-established player with a commitment to providing high-quality and affordable healthcare solutions.

Alembic Pharmaceuticals, a largecap company in the pharmaceuticals and drugs industry, has been downgraded to a 'Hold' by MarketsMOJO due to its high management efficiency, low debt to EBITDA ratio, and positive financial results. However, the company's poor long-term growth may be a cause for concern.

On October 16, 2024, Alembic Pharmaceuticals' stock gained 3.36%, outperforming the sector by 3.25%. According to MarketsMOJO, the stock call for Alembic Pharmaceuticals is 'Buy', indicating a positive future performance. The stock has been on a consecutive gain for the last 2 days and is currently higher than moving averages, showing a positive trend. It has also outperformed the Sensex in the last 1 day and 1 month, making it a promising investment option in the pharmaceuticals and drugs industry.